GT Biopharma, Inc. (GTBP)

GT Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	7.41	7.11	12.45	47.92	6.28	9.79
Research & Development	5.59	6.47	8.81	9.59	0.49	1.67
Operating Expenses	13	13.58	21.26	57.52	6.76	11.46
Operating Income	-13	-13.58	-21.26	-57.52	-6.76	-11.46
Interest Expense	-0	-0.21	-0.01	-0.72	-3.32	-2.13
Interest & Investment Income	0.76	0.78	0.29	0.04	-	-
Other Non Operating Income (Expenses)	2.58	4.82	0.12	0.21	-0.23	-
EBT Excluding Unusual Items	-9.67	-8.19	-20.85	-57.98	-10.31	-13.59
Gain (Loss) on Sale of Investments	0.02	0.05	-0.03	-0.03	-	-
Gain (Loss) on Sale of Assets	-	-	-	-	-	-20.46
Asset Writedown	-	-	-	-	-	-4.6
Legal Settlements	-	-	-	-	-5.38	-
Other Unusual Items	0.01	0.55	-	-	-12.6	-
Pretax Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Earnings From Continuing Operations	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Net Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Net Income to Common	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Shares Outstanding (Basic)	1	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	1	0	0
Shares Change (YoY)	33.88%	26.87%	13.19%	542.06%	29.59%	14.50%
EPS (Basic)	-6.78	-5.64	-19.66	-61.81	-193.58	-342.62
EPS (Diluted)	-6.78	-5.64	-19.66	-61.81	-193.58	-342.62
Free Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.66
Free Cash Flow Per Share	-7.11	-6.57	-14.33	-16.63	-49.68	-32.44
EBITDA	-	-	-	-	-6.76	-11.45
D&A For EBITDA	-	-	-	-	0	0
EBIT	-13	-13.58	-21.26	-57.52	-6.76	-11.46

Source: S&P Capital IQ. Standard template.